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Patient age is related to decision-making,
treatment selection, and perceived quality of life
in breast cancer survivors
Terence T Sio1,2*†, Kenneth Chang2†, Ritujith Jayakrishnan2, Difu Wu1, Mary Politi3, Dominique Malacarne1,
James Saletnik4 and Maureen Chung1,5
Abstract
Background: Patients with breast cancer must choose among a variety of treatment options when first diagnosed.
Patient age, independent of extent of disease, is also related to quality of life. This study examined the impact of
patient age on treatment selected, factors influencing this selection, and perceived quality of life.
Methods: A 62-question survey evaluating breast cancer treatment and quality of life was mailed to breast cancer
survivors. Responses were stratified by age (<50, 50-65, >65 years) and extent of disease.
Results: Of the 1,131 surveys mailed, 402 were included for analysis. There were 104, 179, and 119 women aged
<50, 50-65, and >65 years, respectively. The median patient age was 58 years, and the average interval from diagnosis
to survey participation was 31.5 months.
Conclusions: Young women were more likely to have undergone aggressive therapies and had better physical
functioning than old women. Old patients reported good quality of life and body image. Clinicians should consider
patient age when discussing breast cancer treatment options.
Keywords: Breast cancer, Oncology, Age, Decision-making, Quality of life
Background
Early detection and improved multimodality therapy have
improved breast cancer survival [1]. When first diagnosed,
patients with breast cancer must make decisions about
the type of surgery and adjuvant therapy, each with its
own risks and benefits. The decision-making process is
complex, and is influenced by multiple factors including
patient age, co-morbidities, ethnicity, education, and avail-
ability of visual and written hand-outs. Patient age is so
important that it has been proposed as a determinant of
educational and counseling strategies [2,3].
Age at diagnosis may also influence patient behavior
and outcome. Older women prefer to take a more passive
role in decision-making, relying heavily on their doctors’
recommendations [3], whereas younger women are more
actively involved in treatment decisions, seeking informa-
tion from multiple sources such as the Internet, friends,
family members, and support groups. It has been found
that patients provided with a greater amount of medical
information were associated with less depression and im-
proved quality of life [4]. In the same study, patients who
were satisfied with their participation in the decision-
making process were also found to be less depressed.
Younger women may desire treatments that they perceive
increase life expectancy, while older women may prefer
treatments that maximize quality of life [5,6].
The current study was a retrospective analysis of treat-
ment selection and perceived quality of life in a cohort
of breast cancer survivors. We hypothesized that age at
diagnosis of breast cancer significantly influenced patient
selection of type and duration of therapy, independent
of extent of disease, and that it was directly related to
perceived quality of life after treatment. A cross-sectional
and correlational study design was used.
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Methods
The Comprehensive Cancer Center of Rhode Island Hos-
pital is a tertiary cancer center that treats approximately
one-third of all patients diagnosed with breast cancer in
Rhode Island. All breast cancer cases are presented pro-
spectively at the multidisciplinary breast tumor board and
recorded in the Rhode Island Hospital Breast Cancer data-
base. Patients with breast cancer diagnosed from January
2004 to June 2007 were identified from this database.
Female patients with invasive breast cancer or ductal car-
cinoma in situ without known recurrent disease were in-
cluded. Male patients were excluded.
A survey evaluating breast cancer treatment and qual-
ity of life was mailed to patients with breast cancer on
15 July 2008 (Additional file 1). Patients were asked to
complete the survey and return it anonymously in a pre-
stamped addressed envelope. A raffle was used to in-
crease survey participation, but the raffle form was
returned in a separate pre-stamped addressed envelope
to protect the anonymity of participants. Both English
and Spanish versions of the survey were available. The
English version of the survey was mailed initially with
information on how to obtain the Spanish version in-
cluded at the top of the survey. This study was approved
by the Rhode Island Hospital Institutional Review Board.
The European Organization for Research and Treat-
ment of Cancer (EORTC) QLQ-C30 [7] and BR23 [8]
questionnaires were utilized in the survey. The QLQ-
C30 module includes global health, functional, and
symptom subscales which are robust survey tools for
psychometric evaluation and reproducible across popu-
lation [7]. The BR23 module evaluates functional and
treatment-related symptoms specific to breast cancer, in-
cluding body image questions. Additionally, the survey
included 56 independently developed questions (supple-
mentary section) related to cancer characteristics (4),
demographics (10), extent of disease (2), use and type of
surgery (6), radiotherapy (6), chemotherapy (7), anti-
hormones (5), support systems (10), and perception of
therapies (6). Decisions about treatment were collected
by asking patients to identify the surgery their clinician
recommended, the reason for the recommendation, if
known, and the surgery chosen. The survey also asked
participants to identify whether radiotherapy, anti-
hormone medication, or chemotherapy was recom-
mended, and their final treatment selected. Patients were
provided a list of personal, social, and professional sup-
port structures, and were asked to select the three which
most influenced their treatment decision. Eight ques-
tions assessed how patients felt about their treatment
choices and perceived quality of life. The Decision Re-
gret Scale, a validated five-item scale for measuring re-
gret after treatment choices, was used to assess patient
satisfaction with treatment selected [9]. Perceived quality
of life was measured by the EORTC QLQ-C30 [7] and
the QLQ-BR23 [8], and included questions about fear of
recurrence and death.
We used the average age at onset of menopause
(50 years) and the qualifying age for Medicare benefits
(65 years) to divide patients into three age groups: young
(<50 years), middle-aged (50-65 years), and old (>65 years).
Extent of disease (local represented disease confined to
the breast and regional indicated disease that had spread
to regional lymph nodes) and treatment differences were
analyzed for each age group. Correlations between quality
of life and social support, decision regret, education, and
income were determined. Raw scores were calculated ac-
cording to the Likert scale of individual surveyed items.
Linear transformation was used to convert raw scores of
global health status and functional scales to a scale of 0 to
100, with 100 being highest level of function and quality of
life. Symptom scales (examples: lymphedema, hair loss)
were scored from 0-100, with 100 being most symptom-
atic. Future perspective of patients was scored from 0-
100, with 100 being most optimistic about their health and
prognosis. The Decision Regret Scale ranged from 1-5,
with 5 being strongly agree.
Statistical analysis
A chi-square test was used to compare categorical re-
sults and variables across age groups. Fisher’s exact test
was used to calculate P-values when 20% of the cells had
values below 5. For continuous variables, analysis of
variance (ANOVA) or Kruskal-Wallis tests for three or
more groups (when the data were skewed) were con-
ducted. Logistic regression models were used for con-
tinuous predictor variables with dichotomous outcome
variables. The statistical significance was set at P < 0.05.
Data were analyzed using SAS version 9.2 software.
Results
Demographics
Of 1,131 surveys mailed, 525 (46%) were returned and
402 were used for analysis (111 were excluded from ana-
lysis because they did not meet inclusion criteria due to
factors such as unknown year of diagnosis or incomplete
surveys; 12 additional patients were excluded from the
analysis due to systemic disease at initial diagnosis). No
respondents requested the survey in Spanish. The me-
dian patient age was 58 years (range 29 to 97), and
96.3% of the surveyed population was Caucasian. The aver-
age interval between diagnosis and survey completion was
31.5 months and did not vary by age group (P = 0.25).
Stratified by age, patient characteristics and extent of
disease are summarized in Table 1. There were 104
(26%) young women with an age less than 50 years old,
179 (44%) middle-aged women 50 to 65 years old, and
119 (30%) old women greater than 65 years old. Young
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women were more likely to be diagnosed with regional
disease than old women. Old patients were more likely
to be single/divorced or widowed and less formally edu-
cated. Young patients were more likely to experience fi-
nancial difficulties due to breast cancer. Although they
experience equal rates of disability, younger women
were more likely to be disabled from breast cancer,
while older women were more likely to be disabled from
another health condition. Support group participation
was underutilized across all age groups.
Determinants of treatment decision
The surgical options offered by the physician differed
significantly between each age group (P < 0.0001), with
lumpectomy being more recommended than mastectomy.
Furthermore, physicians were less likely to recommend
chemotherapy to older patients (P < 0.0001). However,
there was no observable difference between age groups for
a physician to recommend radiation therapy (P = 0.24) or
anti-hormone therapy (P = 0.06). When stratified by age
and disease extent, young women were more likely than
old patients to have undergone aggressive therapy (Table 2).
Young and middle-aged women were more likely to have
chosen mastectomy than their older counterparts (P <
0.0002 [odds ratio (OR) = 4.68] and P < 0.011 [OR = 2.46],
respectively). Medical therapies were utilized to a greater
extent in the young age groups (Table 2). For women with
localized disease, young women were more likely to have
received chemotherapy than middle-aged or old women
(P = 0.027, OR = 1.98). Similar results were obtained for
women with regional disease (P = 0.014, OR = 9.59).
The three most important factors that influenced treat-
ment choice were surgeon’s recommendation (83.1%), de-
sire for longevity (72.6%), and family or significant others
(59.1%). Young patients (87.9%) were more likely to want
to live as long as possible compared to middle-aged
(71.1%) and old women (67.7%) (P = 0.0016). Factors that
influenced choice of treatment but had no statistically
significant difference by age groups were self-image
(P = 0.74), treatment side effects (P = 0.74), other factors
(friends, cost, religion) (P = 0.61), and length of therapy
(P = 0.13). Overall, 90.7% of patients were “satisfied” or
“very satisfied” with the treatment information provided
by their physicians. The majority of patients reported little
to no regret for the treatments that they eventually chose:
89%, 89%, and 86% of patients reported no or mild regret
(scores, 0-25) among the young, middle-aged, and old
women, respectively (P = 0.74).
Quality of life
In general, old women reported poorer general health and
functioning than middle-aged and young women (Table 3).
Most respondents had good quality of life with minimal
treatment-related symptoms. Across age groups, there
was no difference in morbidity associated with side effects
(for example, alopecia and lymphedema) from cancer
therapies. Nevertheless, young women had poor body
image compared to old women. Young women were also
Table 1 Demographics and cancer characteristics of study cohort, stratified by age
Age < 50 Age 50-65 Age >65 P*
n (%) n (%) n (%)
Extent of disease
Confined to the breast (local) 63 (63.0) 127 (79.9) 81 (79.4)
0.011
Lymph node involvement (regional) 37 (37.0) 32 (20.1) 21 (20.6)
Caucasian 99 (98.0) 172 (96.1) 113 (95.0) 0.870
Marital status
Single/divorced/widowed 21 (20.2) 48 (26.8) 56 (47.5)
<0.001
Married/partnered 83 (79.8) 131 (73.2) 62 (52.5)
Education beyond high school 82 (78.8) 120 (67.0) 53 (44.5) <0.001
Support group participation 11 (10.7) 18 (10.2) 10 (8.5) 0.912
Has one or more children 83 (79.8) 142 (79.3) 106 (89.1) 0.093
Financial difficulties due to breast cancer
Not at all/a little 86 (84.3) 159 (89.8) 110 (94.0)
0.063
Quite a bit/very much 16 (15.7) 18 (10.2) 7 (6.0)
Has disability 13 (12.6) 18 (10.2) 14 (11.8) 0.993
From breast cancer 6 (5.8) 1 (0.6) 0 (0.0)
0.010From breast cancer and other condition 4 (3.9) 8 (4.5) 4 (3.4)
Unrelated to breast cancer 2 (1.9) 7 (4.0) 9 (7.6)
*P values apply to comparison across all three age groups.
Sio et al. World Journal of Surgical Oncology 2014, 12:230 Page 3 of 8
http://www.wjso.com/content/12/1/230
Table 2 Extent of disease and cancer therapy stratified by patient age
Total number of patients in each age group (N) Age <50 Age 50-65 Age >65 P1
n (%)2 n (%)2 n (%)2
N = 104 N = 179 N = 119
Surgery for disease localized to the breast
0.002
Lumpectomy 41 (39.4) 91 (50.8) 68 (57.1)
Mastectomy 20 (19.2) 30 (16.8) 6 (5.0)
Surgery for regional disease
0.158
Lumpectomy 16 (15.4) 20 (11.2) 12 (10.1)
Mastectomy 20 (19.2) 11 (6.1) 6 (5.0)
Prophylactic mastectomy 12 (11.5) 19 (10.6) 4 (3.4) 0.046
Systemic chemotherapy
For disease localized to the breast 24 (23.1) 31 (17.3) 10 (8.4) 0.027
For regional disease 34 (32.7) 25 (14.0) 14 (11.7) 0.014
Radiation therapy
For disease localized to the breast 37 (35.6) 80 (44.7) 52 (43.7) 0.125
For regional disease 31 (29.8) 25 (14.0) 17 (14.3) 0.921
Anti-hormone therapy 72 (69.2) 107 (59.8) 52 (43.7) 0.089
1P values apply to comparison across all three age groups.
2The percentages in the table were generated by dividing the number of patients who fell under the corresponding criteria by the total number of patients in the
age group as listed; due to missing values, some percentages may not add up to unity.
Age and extent of disease influenced surgical therapy. Independent of age, patients with regional breast cancer were more likely to have had a mastectomy.
Young patients with localized breast cancer were also more likely to have had a mastectomy than their older counterparts. Patient age also influenced systemic
adjuvant therapy. Young patients with breast cancer were more likely to have received cytotoxic chemotherapy and/or anti-hormonal therapy. No difference in
receipt of breast radiotherapy was observed based on patient age. The odds ratio of choosing mastectomy for young women (<50) and older women >65 was
4.186 (confidence interval 1.996 to 8.781, P < 0.02). The odds ratio of choosing mastectomy for women 50-65 compared to those >65 was 2.526 (confidence
interval 1.238 to 5.152, P < 0.01).
Table 3 Quality-of-life characteristics by age
Age <50 Age 50-65 Age >65 P*
Mean (SD) Mean (SD) Mean (SD)
Global health status (2) 83.4 (19.8) 84.1 (18.3) 80.5 (17.5) 0.057
Physical functioning (5) 89.7 (16.5) 86.7 (17.8) 78.9 (21.3) <0.001
Role functioning (2) 85.9 (27.4) 86.7 (24.4) 90.3 (18.0) 0.839
Body image (4) 69.7 (29.6) 82.8 (22.4) 90.4 (18.2) <0.001
Sexual functioning (2) 38.8 (24.5) 27.6 (26.2) 16.2 (22.6) <0.001
Sexual enjoyment (1) 56.7 (33.0) 45.6 (34.6) 31.5 (33.0) <0.0002
Future perspective (1) 46.7 (34.9) 55.2 (32.0) 70.6 (28.3) <0.001
Side effects from chemotherapy (8)# 17.3 (16.8) 16.0 (16.3) 13.3 (13.5) 0.107
Breast symptoms (4)# 15.7 (18.5) 15.7 (19.3) 10.7 (11.8) 0.210
Arm symptoms (3)# 17.0 (26.2) 13.1 (21.4) 8.4 (13.9) 0.135
Distress from loss of hair (3)# 9.8 (25.0) 17.2 (31.7) 19.4 (31.1) 0.092
QLQ-BR23 total (23) 75.1 (14.3) 78.1 (14.5) 82.3 (10.8) <0.001
Parentheses indicate number of questions asked in each subscale.
#Symptom scales applied. *P values apply to comparison among all three age groups. SD represents standard deviation. Nonparametric Kruskal-Wallis tests were
used for comparison.
The survey results of the EORTC QLQ-C30 and BR23 subscales are shown here, stratified by age group. Overall, older patients reported a better quality of life after
breast cancer therapy. Although younger patients with breast cancer reported better physical functioning, older patients had a better body image. All patients
reported equivalent treatment-related side effects.
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more concerned about recurrence and dying compared to
middle-aged and old women. Women with regional dis-
ease worried more about recurrence and death, compared
to women with disease confined to the breast (Figure 1).
After controlling for extent of disease, age was signifi-
cantly related to physical functioning (P < 0.001) and fu-
ture perspective (P < 0.001), but was not related to global
health status (P > 0.06) or breast symptoms (P > 0.06). Ex-
tent of disease was significantly related to global health
status (F = 4.2, P < 0.04, data not tabulated). Women with
regional disease reported poor quality of life compared
with those with local disease (79.1 versus 83.7). Compared
to those with local disease, they were also more affected in
physical (80.5 versus 86.6, F = 7.05, P < 0.008) and role
functions (83.3 versus 89.3, F = 4.5, P < 0.04). These data
suggested that extent of disease may independently affect
quality of life.
Menopausal status is a potential confounder in health-
related quality-of-life analysis, as it is physiologically re-
lated to age and sexual health. Menopause has been
shown to significantly diminish the quality of life of
women [10]. After controlling for menopausal status,
age was significantly related to sexual functioning (P <
0.0001) and enjoyment (P < 0.0009), with old women
more negatively affected. Menopausal status was also re-
lated to body image (F = 16.45, P < 0.0001 favoring older)
and future perspectives (F = 5.54, P < 0.02 favoring older).
However, there was no relationship between menopausal
status and total EORTC QLQ-BR23 score (F = 1.56, P =
0.21), arm symptoms (F = 0.01, P = 0.92), breast symptoms
(F = 0.90, P = 0.34), chemotherapy side effects (F = 0.04,
P = 0.84), and alopecia-associated distress (F = 0.27, P =
0.60). Old women were more likely to have received or
were recommended anti-hormonal medication. After con-
trolling for anti-hormonal therapy, age was significantly
related to total BR23 score (F = 6.61, P < 0.002), body
image (F = 16.79, P < 0.0001), and sexual function (F =
13.82, P < 0.0001). Age was significantly related to body
image (P < 0.0001) after controlling for mastectomy use.
Discussion
Breast cancer therapy consists of multimodality treat-
ment ranging from breast conservation to mastectomy,
whole or partial radiotherapy of varying duration, select-
ive use of anti-hormone medication, and chemotherapy
regimens that differ in duration and morbidity. Our data
supported the original hypothesis that age is related to
treatment choice; young women were more likely to
choose aggressive therapies, even when diagnosed with
localized disease. This result is consistent with the obser-
vation that young women may select more aggressive
treatments in order to maximize their survival [11,12].
By contrast, Bleicher and colleagues [3] reported no dif-
ference in mastectomy choice by age, and a study from
the University Hospital of Wales reported that older pa-
tients were more likely to choose mastectomy as a treat-
ment option [13].
Increased awareness of family history may increase the
likelihood of young patients pursuing mastectomy. Al-
though these variables were not included in our survey,
it has been reported that women with a family history of
breast cancer were more likely to choose mastectomy as
their breast cancer treatment option [14]. Women with
a family history of breast cancer are also more likely to
undergo prophylactic mastectomy [15]. This may par-
tially explain why young women in our study were more
likely to undergo more invasive surgery, including
prophylactic mastectomy, because the risk of recurrence
and desire for longevity are significant patient concerns.
The need for maximal survival may influence surgical
treatment choice [16]. Patients with breast cancer may
opt for mastectomy, as they perceive that this procedure
increases cancer survival. Although local recurrence de-
creases with mastectomy, breast-conserving surgery is
no less efficacious than mastectomy with regard to long-
term survival [16]. In general, a higher education level
was associated with opting for breast conservation,
which may be due to a better understanding of risk re-
currence (Surveillance, Epidemiology, and End Results
Figure 1 Worries about recurrence and dying in patients with breast cancer.
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(SEER) Program, Fast Stats-Breast Cancer). However, young
patients in our study were better educated but less likely
to choose breast-conserving surgery. The increased use of
mastectomy by young women may be a reflection of feel-
ing comfortable with invasive surgery due to having a
greater social support network of family and friends. In
one prior study, elderly breast cancer survivors reported
having less social support network mechanisms than
young women [17]. In the population studied in this re-
port, an increase in support group utilization across all
age groups may present a future research direction.
In addition to choosing less invasive surgery, older
women were also less likely to receive chemotherapy.
These women were less likely to use anti-hormone
medication despite their physicians’ recommendations.
Furthermore, older women tend to have poorer general
health than young women, and are more likely to have
medical co-morbidities [17]. This may, in part, explain
why more older women chose not to receive chemother-
apy or anti-hormones as part of their breast cancer
treatment.
In our study, physician recommendation was of pri-
mary significance in influencing the patient’s selection of
treatment. Physicians may be less likely to recommend
medical interventions to older patients because of poten-
tial complications and increased morbidity [18]. The au-
thority for decisions regarding treatment may not be
equally shared between physicians and patients. Physi-
cians may also underestimate the influence of the words
they choose to describe extent of disease and potential
treatments options to patients [19].
Overall, patients in this study reported being satisfied
with information regarding treatment options. In addition,
83% of survey participants stated that their surgeon’s rec-
ommendation was a major influence on treatment selec-
tion options. A previous study which reviewed factors
influencing surgery choice in women also showed similar
results [20]. Another study showed that 95% of study
participants were satisfied with time spent discussing
treatment options with their surgeons, underscoring a sur-
geon’s influence on the type of breast cancer surgery se-
lected [21]. The congruency between the patients’ and
physicians’ opinions has been associated with treatment
satisfaction, which in turn correlates with higher levels of
quality of life [22]. Similarly, another group found that the
more the patient was involved in decision-making, the
better the quality of life that she seemed to achieve by as-
sociation [23,24]. These results reiterate the importance of
physician’s participation in empowering and educating
patients with breast cancer regarding their treatment
options.
Most breast cancer survivors reported preserved quality
of life and function in this study. Breast cancer survivors’
quality of life improves with time and is comparable to the
general population five years after treatment [25]. Over
longer time periods, most breast cancer survivors have
functional scales comparable to those of the general popu-
lation [26,27]. Interestingly, patients in this study had a
good quality of life after only an average of 31 months
after diagnosis, suggesting that a return to function oc-
curs much earlier than previously reported. There was
no difference in side effects between the different age
groups but, after controlling for extent of disease, age
was significantly related to arm symptoms. In other
studies, quality of life was lower in breast cancer survi-
vors who experienced arm symptoms, with or without
lymphedema [28]. This might be expected in younger
women who undergo more aggressive surgery and/or
are more physically active and therefore more likely to
notice functional limitations.
Poorer body image in young breast cancer survivors
may reflect increased selection of mastectomy as a treat-
ment option [29]. Concerns for appearance have led
younger patients to opt for lumpectomy more frequently
compared to their older counterparts [30]. It has also
been reported that young patients significantly experi-
enced more worries regarding their finances and future
health, and had poorer emotional and social functioning
compared to the older generation [31]. Although socio-
economic status had no correlation with treatment deci-
sions or self-perceived health-related quality of life,
factors such as annual household income, disability sta-
tus, and insurance coverage options may be barriers to
health care access and consequently outcome in some
communities [32].
There are several limitations to this study. The conclu-
sions of the study are based solely on patient responses
and may reflect a recall bias. Our survey tools were
based on the EORTC QLQ-C30 and QLQ-BR23 ques-
tionnaires, which do not evaluate social and spiritual
quality of life [33]. Although the survey was generated in
an academic urban center, the vast majority of respon-
dents were Caucasian with private health insurance.
Thus, future studies which incorporate minority popula-
tions will be desirable, since cultural belief may repre-
sent a major factor in medical decision-making.
The survey response sample data set in our study was
self-selected. Although the survey was mailed to all pa-
tients who were treated between 2004 and 2008, those
who responded to the survey might have had better
quality of life and health outcomes than those who chose
not to respond. Breast cancer survivors may report fewer
symptoms and better quality of life if they have not had
a recurrence or a therapy-related complication [34]. This
may have introduced a non-random sampling bias into
the study results. Characteristics of survey participants
and non-participants could not be compared because of
the anonymous nature of the study.
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Perceived quality of life may differ based on ethnicity
[35] or on whether patients had private health care in-
surance. The initial survey was written in an English lan-
guage format, which may have decreased the survey
response rate of patients who speak English as a second
language or not at all. A Spanish language survey format
was also available to patients but only upon request.
Conclusions
This study demonstrated that patient age plays a major
role in how patients with breast cancer choose their treat-
ments and its impact on perceived quality of life. Add-
itionally, age is significantly related to psychosocial well-
being in breast cancer survivors. Breast cancer survivors
younger than 50 years were more likely to choose aggres-
sive therapies compared to their older counterparts, while
older women wanted the least disruptive treatments,
choosing treatments that maximized quality of life. Age
was related to treatment decision-making and quality of
life in this cohort of breast cancer survivors, which vali-
dated the findings of previous similar studies. Regardless of
age, most breast cancer survivors reported little to no re-
gret regarding their treatment choices, with similar factors
influencing treatment selection across all ages. A patient’s
age should be considered when counseling patients about
treatment options and discussing long-term quality-of-life
goals in order to best individualize breast cancer care.
Additional file
Additional file 1: A survey on quality of life for patients with breast
cancer.
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